OBJECTIVE: To determine whether small ubiquitin-related modifier (SUMO)ylation of lysine 107 plays a role in regulating the activity of peroxisome proliferator-activated receptor gamma (PPARgamma). RESEARCH METHODS AND PROCEDURES: Transient expression of wild-type and K107R-PPARgamma2 in the NIH 3T3 fibroblast cell line was carried out in conjunction with half-life studies, luciferase activity assays, and indirect immunofluorescence localization studies. Additional in vitro analysis was carried out using recombinant SUMOylation pathway proteins along with in vitro transcribed and translated wild-type or K107R-PPARgamma2 to examine the SUMO-1 modification state of wild-type and SUMO-deficient K107R-PPARgamma2. RESULTS: While examining PPARgamma2 for potential ubiquitylation sites, we identified a strong consensus site for SUMO modification that contains lysine 107. In vitro, SUMOylation studies showed that lysine 107 of PPARgamma2 is a major SUMOylation site and that at least one other SUMOylation site is present in PPARgamma. In addition, our results demonstrated that SUMO-1 affects PPARgamma stability and transcriptional activity but not the nuclear localization of PPARgamma. DISCUSSION: These results indicated that SUMOylation plays a role in regulating PPARgamma, both indirectly and directly by modification of lysine 107. Because PPARgamma is regulated in numerous animal models of obesity, understanding the covalent modifications of PPARgamma may enhance our understanding of the metabolic syndrome.
OBJECTIVE: To determine whether small ubiquitin-related modifier (SUMO)ylation of lysine 107 plays a role in regulating the activity of peroxisome proliferator-activated receptor gamma (PPARgamma). RESEARCH METHODS AND PROCEDURES: Transient expression of wild-type and K107R-PPARgamma2 in the NIH 3T3 fibroblast cell line was carried out in conjunction with half-life studies, luciferase activity assays, and indirect immunofluorescence localization studies. Additional in vitro analysis was carried out using recombinant SUMOylation pathway proteins along with in vitro transcribed and translated wild-type or K107R-PPARgamma2 to examine the SUMO-1 modification state of wild-type and SUMO-deficient K107R-PPARgamma2. RESULTS: While examining PPARgamma2 for potential ubiquitylation sites, we identified a strong consensus site for SUMO modification that contains lysine 107. In vitro, SUMOylation studies showed that lysine 107 of PPARgamma2 is a major SUMOylation site and that at least one other SUMOylation site is present in PPARgamma. In addition, our results demonstrated that SUMO-1 affects PPARgamma stability and transcriptional activity but not the nuclear localization of PPARgamma. DISCUSSION: These results indicated that SUMOylation plays a role in regulating PPARgamma, both indirectly and directly by modification of lysine 107. Because PPARgamma is regulated in numerous animal models of obesity, understanding the covalent modifications of PPARgamma may enhance our understanding of the metabolic syndrome.
Authors: Serena Ghisletti; Wendy Huang; Sumito Ogawa; Gabriel Pascual; Mu-En Lin; Timothy M Willson; Michael G Rosenfeld; Christopher K Glass Journal: Mol Cell Date: 2007-01-12 Impact factor: 17.970
Authors: Brahmchetna Bedi; Nicholas M Maurice; Vincent T Ciavatta; K Sabrina Lynn; Zhihong Yuan; Samuel A Molina; Myungsoo Joo; William R Tyor; Joanna B Goldberg; Michael Koval; C Michael Hart; Ruxana T Sadikot Journal: FASEB J Date: 2017-04-25 Impact factor: 5.191
Authors: Chongben Zhang; Yingke He; Mitsuhara Okutsu; Lai Chun Ong; Yi Jin; Lin Zheng; Pierce Chow; Sidney Yu; Mei Zhang; Zhen Yan Journal: Am J Physiol Endocrinol Metab Date: 2013-06-25 Impact factor: 4.310